Welcome to the 6th Dermatology Drug Development Summit for
Inflammatory Skin Diseases

The 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall. Amidst the immense range and a steady stream of the novel, topical, and systemic agents entering exciting early phases, now is the time to gain insight from other leaders in the space.

As the world’s leading and only forum committed to overcoming significant R&D hurdles and sharing best practices for advancing efficacious next-generation therapies for chronic inflammatory skin conditions, can you really afford to miss out?

With the rising demand for patient-specific and alternative treatment options, along with some first-in-class treatments in the likes of Alopecia Areata – the 6th annual meeting addresses genetic discoveriesantibody drug developmentdelivery strategies, and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe, inflammatory skin conditions.

Ensure you join this year’s 150+ expert community in-person to:

Bulletpoint 1
Bulletpoint 2
Bulletpoint 3
Bulletpoint 4

Uncover recent studies evaluating critical inflammatory and auto-immune pathways

Gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, versus IL-17 associated diseases.

Assess emerging efficacious targeted approaches in the plethora of conditions outside of these pathways.

Obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet needs such as Hidradenitis Suppurativa, Vitiligo, Rare Disease, and Alopecia Areata.

Testimonials from the 5th Dermatology Drug Development Summit

“A great opportunity to spend a few days with leading drug development leaders and companies that are shaping the future of dermatology” - Contract Pharmaceuticals 

“High quality conference providing insights on the opportunities and challenges in dermatology drug development” – LEO Pharma

“Great list of speakers highlighting the significant new advances in inflammatory skin disease therapy” – Nocion Therapeutics

2022 Industry Leading Speaker Faculty

Lotus Mallbris

Vice President of Global Immunology Development & Medical Affairs

Eli Lilly and Company

Primal Kaur

Vice President Global Development

Amgen

Kristian Reich

Founder & Chief Scientific Officer

MoonLake Immunotherapeutics

Andy Blauvelt MD M.B.A

President

Oregon Medical Research Center

Arash Mostaghimi

Assistant Professor, Director of Inpatient Dermatology Consult Service

Brigham & Women’s Hospital

Ricardo Rojo Cellas

Global Clinical Lead

Janssen

Suma Krishnan

Chief Executive Officer

Krystal Biotech

Henrique Teixeira

Group Scientific Director Immunology Clinical Development

AbbVie

2022 Partners:

Expertise Partners

Tergus pharma Logo
Therapeutics Inc Logo
Scarletred Logo
Logo_Nordic_Bioscience_Standard

Event Partner

Curebase Logo (High Res)
catawba
altasciences-logo

Program Partners

Innovation Partners

CPL Logo
Quantificare Logo
210528 NUV Logo_Blau_OhneZusatz

Exhibition Partners

TKL Research Logo
DPT
Dow Development Laboratories Logo
DermTech Logo
MedPharm logo
Genoskin-logo